Barry Moze - 28 Jul 2021 Form 4 Insider Report for Horizon Therapeutics Public Ltd Co

Role
EVP, Chief Admin. Officer
Signature
/s/ Miles W. McHugh, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
28 Jul 2021
Net transactions value
-$329,538
Form type
4
Filing time
30 Jul 2021, 16:26:06 UTC
Previous filing
09 Jul 2021
Next filing
05 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HZNP Ordinary Shares Award $0 +7,257 +10% $0.000000 78,896 28 Jul 2021 Direct F1
transaction HZNP Ordinary Shares Tax liability $329,538 -3,215 -4.1% $102.50 75,681 28 Jul 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HZNP Performance Restricted Stock Units (PSUs) Award $0 +14,514 $0.000000 14,514 28 Jul 2021 Ordinary Shares 14,514 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On July 28, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023.
F2 Each PSU represents a contingent right to receive one ordinary share of the Issuer.